United States : U.S. FDA Approves CARVYKTI (ciltacabtagene autoleucel), Janssens First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Media coverage

• Title	United States : U.S. FDA Approves CARVYKTI (ciltacabtagene autoleucel), Janssens First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
  Media name/outlet	TendersInfo – News
  Country/Territory	India
  Date	7/03/22
  Persons	Sundar Jagannath

• Title	United States : U.S. FDA Approves CARVYKTI (ciltacabtagene autoleucel), Janssens First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
  Media name/outlet	Mena Report
  Country/Territory	United Kingdom
  Date	7/03/22
  Persons	Sundar Jagannath